Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.76 |
| ▸ | LMNA | P02545 | 2/20 | 0.71 |
| ▸ | GPBAR1 | Q8TDU6 | 7/20 | 0.70 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.68 |
| ▸ | MAPT | P10636 | 2/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.65 |
| ▸ | NPC1 | O15118 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | HPGD | P15428 | 1/20 | 0.64 |
| ▸ | PLAU | P00749 | 1/20 | 0.63 |
| ▸ | ELANE | P08246 | 1/20 | 0.63 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.63 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30395456 | 1.00 | HSD17B10 (0.76) | HSD17B10LMNAGPBAR1CYP2C19MAPT | |
| Hydrochloric Acid SCHEMBL11554371 | 0.98 | HSD17B10 (0.74) | HSD17B10LMNAGPBAR1CYP2C19MAPT | |
| SCHEMBL27910275 | 0.89 | HSD17B10 (0.78) | HSD17B10LMNAGPBAR1CYP2C19MAPT | |
| SCHEMBL14765558 | 0.88 | MAPT (0.77) | HSD17B10LMNAGPBAR1CYP2C19MAPT | |
| SCHEMBL32679558 | 0.88 | HSD17B10 (0.76) | HSD17B10LMNAGPBAR1CYP2C19MAPT | |
| SCHEMBL315858 | 0.88 | HSD17B10 (0.76) | HSD17B10LMNAGPBAR1CYP2C19MAPT | |
| SCHEMBL10520547 | 0.88 | HSD17B10 (0.76) | HSD17B10LMNAGPBAR1CYP2C19MAPT | |
| SCHEMBL903109 | 0.87 | HSD17B10 (1.00) | HSD17B10LMNAGPBAR1CYP2C19MAPT | |
| SCHEMBL8548060 | 0.87 | HSD17B10 (0.74) | HSD17B10LMNAGPBAR1CYP2C19MAPT | |
| SCHEMBL12457425 | 0.84 | GPBAR1 (0.59) | HSD17B10LMNAGPBAR1CYP2C19MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 146 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180273906-A1 | MICROVESICLE AND STEM CELL COMPOSITIONS FOR THERAPEUTIC APPLICATIONS | IPS HEART | 2018-09-27 | — | — | US | claimed |
| EP-1745009-B1 | HETEROARYL SUBSTITUTED CYCLOHEXYL-1,4-DIAMINE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2012-11-14 | — | — | EP | claimed |
| JP-2007536321-A | — | — | 2007-12-13 | — | — | JP | claimed |
| US-20070129369-A1 | Heteroaryl substituted cyclohexyl-1,4-diamine compounds | GRUENENTHAL GMBH (DE) | 2007-06-07 | — | — | US | claimed |
| EP-1745009-A1 | HETEROARYL SUBSTITUTED CYCLOHEXYL-1,4-DIAMINE DERIVATIVES | Grünenthal GmbH (DE) | 2007-01-24 | — | — | EP | claimed |
| US-20060058351-A1 | Novel ligands that modulate LXR-type receptors and cosmetic/pharmaceutical applications thereof | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2006-03-16 | — | — | US | claimed |
| EP-1599447-A1 | LIGANDS THAT MODULATE LXR-TYPE RECEPTORS | Galderma Research & Development, S.N.C. (FR) | 2005-11-30 | — | — | EP | claimed |
| WO-2005110971-A1 | HETEROARYL SUBSTITUTED CYCLOHEXYL-1,4-DIAMINE DERIVATIVES | Grünenthal GmbH (DE) | 2005-11-24 | — | — | WO | claimed |
| CN-1228332-C | Chemical synthesis method of 3-(2-chlorophenyl)-5-methyl-4-isoxazole formyl chloride | UNIV ZHEJIANG TECHNOLOGY (CN) | 2005-11-23 | — | — | CN | claimed |
| CN-1535960-A | Chemical synthesis method of 3-(2-chlorophenyl)-5-methyl-4-isoxazole formyl chloride | 浙江工业大学 | 2004-10-13 | — | — | CN | claimed |
| WO-2004076418-A1 | LIGANDS THAT MODULATE LXR-TYPE RECEPTORS | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2004-09-10 | — | — | WO | claimed |
| US-4007168-A | Process for preparing penicillins derivatives | PALOMO COLL A L | 1977-02-08 | — | — | US | claimed |
| WO-2026085609-A1 | METHODS FOR PRODUCING POLYUNSATURATED FATTY ACIDS FROM AQUACULTURE RESIDUES | LES LABORATOIRES ISO-BIOKEM INC. (CA) | 2026-04-30 | — | — | WO | disclosed |
| EP-4590301-A1 | COMPOUNDS FOR TREATMENT OF INFLAMMATORY PROCESSES | THORNE LIMITED (CA) | 2025-07-30 | — | — | EP | disclosed |
| CN-114058321-B | Encapsulant for display | 日本化药株式会社 | 2025-05-23 | — | — | CN | disclosed |
| CN-119463228-A | Glove manufacturing method | 日本瑞翁株式会社 | 2025-02-18 | — | — | CN | disclosed |
| US-4230849-A | Process for the activation of carboxylic acids | ANTIBIOTICOS, S.A. (ES) | 1980-10-28 | — | — | US | disclosed |
| US-4172198-A | ANTIBIOTICS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1979-10-23 | — | — | US | disclosed |
| US-4113940-A | ANTIMICROBIAL | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1978-09-12 | — | — | US | disclosed |
| US-3984397-A | CYCLIZATION | FUJISAWA PHARMACEUTICAL CO., LTD. (JA) | 1976-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180273906-A1 | MICROVESICLE AND STEM CELL COMPOSITIONS FOR THERAPEUTIC APPLICATIONS | EXOSC9, EXOSC5, EXOSC4 | HSD17B10 3195/4885LMNA 245/4885GPBAR1 4716/4885 |
| US-20070129369-A1 | Heteroaryl substituted cyclohexyl-1,4-diamine compounds | DDC, DPYD, PKD1 | HSD17B10 394/4885LMNA 2080/4885GPBAR1 181/4885 |
| US-20060058351-A1 | Novel ligands that modulate LXR-type receptors and cosmetic/pharmaceutical applications thereof | NR1H2, NR1H3, RXRG | HSD17B10 235/4885LMNA 1835/4885GPBAR1 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.